Historical Valuation
Krystal Biotech Inc (KRYS) is now in the Undervalued zone, suggesting that its current forward PS ratio of 13.92 is considered Undervalued compared with the five-year average of -14.32. The fair price of Krystal Biotech Inc (KRYS) is between 406.60 to 451.41 according to relative valuation methord. Compared to the current price of 261.41 USD , Krystal Biotech Inc is Undervalued By 35.71%.
Relative Value
Fair Zone
406.60-451.41
Current Price：261.41
35.71%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Krystal Biotech Inc (KRYS) has a current Price-to-Book (P/B) ratio of 6.29. Compared to its 3-year average P/B ratio of 5.13 , the current P/B ratio is approximately 22.62% higher. Relative to its 5-year average P/B ratio of 4.42, the current P/B ratio is about 42.18% higher. Krystal Biotech Inc (KRYS) has a Forward Free Cash Flow (FCF) yield of approximately 2.31%. Compared to its 3-year average FCF yield of -1.05%, the current FCF yield is approximately -320.19% lower. Relative to its 5-year average FCF yield of -3.23% , the current FCF yield is about -171.52% lower.
P/B
Median3y
5.13
Median5y
4.42
FCF Yield
Median3y
-1.05
Median5y
-3.23
Competitors Valuation Multiple
AI Analysis for KRYS
The average P/S ratio for KRYS competitors is 62.94, providing a benchmark for relative valuation. Krystal Biotech Inc Corp (KRYS.O) exhibits a P/S ratio of 13.92, which is -77.88% above the industry average. Given its robust revenue growth of 16.65%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for KRYS
1Y
3Y
5Y
Market capitalization of KRYS increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of KRYS in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is KRYS currently overvalued or undervalued?
Krystal Biotech Inc (KRYS) is now in the Undervalued zone, suggesting that its current forward PS ratio of 13.92 is considered Undervalued compared with the five-year average of -14.32. The fair price of Krystal Biotech Inc (KRYS) is between 406.60 to 451.41 according to relative valuation methord. Compared to the current price of 261.41 USD , Krystal Biotech Inc is Undervalued By 35.71% .
What is Krystal Biotech Inc (KRYS) fair value?
KRYS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Krystal Biotech Inc (KRYS) is between 406.60 to 451.41 according to relative valuation methord.
How does KRYS's valuation metrics compare to the industry average?
The average P/S ratio for KRYS's competitors is 62.94, providing a benchmark for relative valuation. Krystal Biotech Inc Corp (KRYS) exhibits a P/S ratio of 13.92, which is -77.88% above the industry average. Given its robust revenue growth of 16.65%, this premium appears unsustainable.
What is the current P/B ratio for Krystal Biotech Inc (KRYS) as of Jan 10 2026?
As of Jan 10 2026, Krystal Biotech Inc (KRYS) has a P/B ratio of 6.29. This indicates that the market values KRYS at 6.29 times its book value.
What is the current FCF Yield for Krystal Biotech Inc (KRYS) as of Jan 10 2026?
As of Jan 10 2026, Krystal Biotech Inc (KRYS) has a FCF Yield of 2.31%. This means that for every dollar of Krystal Biotech Inc’s market capitalization, the company generates 2.31 cents in free cash flow.
What is the current Forward P/E ratio for Krystal Biotech Inc (KRYS) as of Jan 10 2026?
As of Jan 10 2026, Krystal Biotech Inc (KRYS) has a Forward P/E ratio of 34.94. This means the market is willing to pay $34.94 for every dollar of Krystal Biotech Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Krystal Biotech Inc (KRYS) as of Jan 10 2026?
As of Jan 10 2026, Krystal Biotech Inc (KRYS) has a Forward P/S ratio of 13.92. This means the market is valuing KRYS at $13.92 for every dollar of expected revenue over the next 12 months.